Combined Immunoscore for Prognostic Stratification of Early Stage Non-Small-Cell Lung Cancer.
NSCLC
PD-L1
early stage
immune microenvironment
prognosis
Journal
Frontiers in oncology
ISSN: 2234-943X
Titre abrégé: Front Oncol
Pays: Switzerland
ID NLM: 101568867
Informations de publication
Date de publication:
2020
2020
Historique:
received:
22
05
2020
accepted:
27
08
2020
entrez:
19
10
2020
pubmed:
20
10
2020
medline:
20
10
2020
Statut:
epublish
Résumé
To date, no combined immunoscore has been evaluated for prognostic stratification of early stage non-small-cell lung cancer (NSCLC). The main goal of this study was to investigate the prognostic impact of programmed death ligand 1 (PD-L1) expression and different immune cell components (CD4+, CD8+ T-lymphocytes, and CD68+ macrophages) in early stage NSCLC patients, distinguishing peritumoral (PT) and intratumoral (IT) localizations. The secondary aim was to identify a combined immunoscore to optimize the prognostic stratification of NSCLC patients. This retrospective study included surgical specimens from consecutive chemo-naive stage II-III radically resected NSCLC patients. Immunohistochemistry was carried out to evaluate PD-L1 expression and to quantify IT and PT CD4+, CD8+ T-lymphocytes, and CD68+ macrophages. The impact of a single marker and of a combination of multiple markers on overall survival (OS) was investigated. Seventy-nine patients were included in the study. PD-L1 expression was associated with worse prognosis (3 years OS: 58% in high- compared with 67% in low-expressing tumors), even though without statistical significance. When integrating PT CD8+, CD4+, and CD68 into a combined PT immunoscore, a significant prognostic stratification of patients was obtained and confirmed at multivariate analysis (3 years OS: 86% in patients with low PT immunoscore vs. 59% in patients with high PT immunoscore, The combined PT immunoscore (CD8+, CD4+, and CD68) integrated with dNLR may be a promising marker for the development of an integrated Tumor, Node, Metastasis (TNM) immunoscore.
Sections du résumé
BACKGROUND
BACKGROUND
To date, no combined immunoscore has been evaluated for prognostic stratification of early stage non-small-cell lung cancer (NSCLC). The main goal of this study was to investigate the prognostic impact of programmed death ligand 1 (PD-L1) expression and different immune cell components (CD4+, CD8+ T-lymphocytes, and CD68+ macrophages) in early stage NSCLC patients, distinguishing peritumoral (PT) and intratumoral (IT) localizations. The secondary aim was to identify a combined immunoscore to optimize the prognostic stratification of NSCLC patients.
METHODS
METHODS
This retrospective study included surgical specimens from consecutive chemo-naive stage II-III radically resected NSCLC patients. Immunohistochemistry was carried out to evaluate PD-L1 expression and to quantify IT and PT CD4+, CD8+ T-lymphocytes, and CD68+ macrophages. The impact of a single marker and of a combination of multiple markers on overall survival (OS) was investigated.
RESULTS
RESULTS
Seventy-nine patients were included in the study. PD-L1 expression was associated with worse prognosis (3 years OS: 58% in high- compared with 67% in low-expressing tumors), even though without statistical significance. When integrating PT CD8+, CD4+, and CD68 into a combined PT immunoscore, a significant prognostic stratification of patients was obtained and confirmed at multivariate analysis (3 years OS: 86% in patients with low PT immunoscore vs. 59% in patients with high PT immunoscore,
CONCLUSION
CONCLUSIONS
The combined PT immunoscore (CD8+, CD4+, and CD68) integrated with dNLR may be a promising marker for the development of an integrated Tumor, Node, Metastasis (TNM) immunoscore.
Identifiants
pubmed: 33072595
doi: 10.3389/fonc.2020.564915
pmc: PMC7544833
doi:
Types de publication
Journal Article
Langues
eng
Pagination
564915Informations de copyright
Copyright © 2020 Boscolo, Fortarezza, Lunardi, Comacchio, Urso, Frega, Menis, Bonanno, Guarneri, Rea, Conte, Calabrese and Pasello.
Références
J Thorac Oncol. 2017 May;12(5):814-823
pubmed: 28132868
Oncotarget. 2017 Aug 12;8(48):83986-83994
pubmed: 29137398
Clin Cancer Res. 2019 Mar 1;25(5):1526-1534
pubmed: 30201760
Oncotarget. 2015 Dec 8;6(39):42053-66
pubmed: 26544728
Adv Anat Pathol. 2017 Nov;24(6):311-335
pubmed: 28777143
Neoplasia. 2015 Nov;17(11):839-48
pubmed: 26678911
Neoplasia. 2019 Mar;21(3):282-293
pubmed: 30743162
World J Surg. 2016 Feb;40(2):365-72
pubmed: 26493696
Clin Lung Cancer. 2018 May;19(3):249-259.e2
pubmed: 29396238
Oncotarget. 2016 Sep 27;7(39):64318-64329
pubmed: 27602763
Ann Oncol. 2016 Feb;27(2):225-32
pubmed: 26578726
Clin Cancer Res. 2015 Jun 1;21(11):2635-43
pubmed: 25680376
JCI Insight. 2016 Sep 8;1(14):
pubmed: 27642636
PeerJ. 2019 Jul 29;7:e7232
pubmed: 31392087
Cancer Med. 2018 Jan;7(1):32-45
pubmed: 29168339
J Thorac Dis. 2018 Feb;10(Suppl 3):S404-S411
pubmed: 29593886
Curr Opin Immunol. 2013 Apr;25(2):261-7
pubmed: 23579076
J Transl Med. 2012 Oct 03;10:205
pubmed: 23034130
Oncotarget. 2016 Nov 1;7(44):72184-72196
pubmed: 27708229
Chest. 2017 Jan;151(1):193-203
pubmed: 27780786
Lung Cancer. 2013 May;80(2):209-15
pubmed: 23384671
Oncotarget. 2019 Dec 24;10(67):7142-7155
pubmed: 31903172
J Clin Oncol. 2008 Jul 20;26(21):3552-9
pubmed: 18506026
Oncotarget. 2019 Jan 15;10(5):561-572
pubmed: 30728907
Nature. 2017 Jan 18;541(7637):321-330
pubmed: 28102259
Exp Lung Res. 2019 Apr - May;45(3-4):76-83
pubmed: 31134811
J Thorac Oncol. 2015 Sep;10(9):1240-1242
pubmed: 26291007